Making money in biotech stocks

High Yield Investor's Samuel Smith shares his thoughts on energy, gold and silver (0:40) Context on yield (11:00) Context on dividend cuts (16:20) Updated thoughts on private credit and Blue Owl (18:30)Show Notes:Blue Owl Capital: The Market Thinks Disaster Is Coming, I Think It ...  Show more

Two of Seeking Alpha's top tech analysts, Amrita Roy and Uttam Dey, share how they approach the sector (1:00) ROI on AI capex; hyperscalers, optical connectivity, memory (11:45) Lumentum bullishness and why gross margins are so important (26:00) Nvidia's peculiar spot (30:30) Tec ...  Show more

From Barcelona to Wall Street — Dr. Josep Bassaganya-Riera’s journey is nothing short of extraordinary. A veterinarian-turned-immunologist, he went on to found multiple biotech companies, take Landos Biopharma public, and lead one of the only private biotech firms with a Phase 3 ...  Show more

Gary Vaughan from Daily Stock Picks highlights ETFs and why setting your risk tolerance as investor is important (0:10). How the macro picture affects his portfolio performance (1:10). Tech earnings: Apple's valuation is concerning, Google monetizing AI, but is Microsoft? High fl ...  Show more

Send us Fan MailIn 2000 I Iost $300,000 in mutual funds that an investment advisor had put my money into. I lost it because I had entrusted my life savings to an industry that does not educate investors nor encourage them to look closely at what that industry is doing with their ...  Show more

Julian Lin updates his views on cannabis REITs IIPR and NewLake Capital (1:15). RIP Cannabis Growth Investor - changed thesis on cannabis MSOs (6:45). Why Green Thumb has done well relative to the sector (13:35). Episode transcripts Show Notes: NewLake Capital: 9.3% Dividend Yiel ...  Show more